Reduced ejection fraction after myocardial infarction: Is it sufficient to justify implantation of a defibrillator?

Chest

Volumn 128, Issue 4, 2005, Pages 2626-2632

  Pascale, Patrizio ^a   Taffe, Patrick ^b   Regamey, Claude ^c   Kappenberger, Lukas ^a   Fromer, Martin ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

Arrhythmia therapy; Artery disease; Cardiology; Coronary artery; Epidemiology; Myocardial infarction

Indexed keywords

ADULT; AGED; ARTICLE; DEFIBRILLATOR; DEVICE; EXPERIENCE; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REVASCULARIZATION; RISK BENEFIT ANALYSIS; SURVIVAL;

EID: 27144479420     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2626     Document Type: Article

References (31)

1. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309:331-336
2. Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of the GISSI-2 data base. Circulation 1993; 88:416-429
3. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s-their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) study. J Am Coll Cardiol 1996; 27:1119-1127
4. Hartikainen JEK, Malik M, Staunton A, et al. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 1996; 28:296-304
5. Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the Multicenter Unsustained Tachycardia Trial. Circulation 2002; 106:2466-2472
6. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674
7. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906
8. Torp-Pedersen C, Kober L, Ball S, et al. The incomplete bucindolol evaluation in acute myocardial infarction trial (BEAT). Eur J Heart Fail 2002; 4:495-499
9. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-1390
10. Jensen-Urstad M, Samad BA, Jensen-Urstad K, et al. Risk assessment in patients with acute myocardial infarction treated with thrombolytic therapy. J Intern Med 2001; 249: 527-537
11. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883
12. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndrome Writing Committee). J Am Coll Cardiol 2001; 38:2114-2130
13. Kizer JR, Cannon CP, McCabe CH, et al. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Am Heart J 1999; 137:79-92
14. Wilber DJ, Zareba W, Jackson Hall W, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004; 109:1082-1084
15. Sheehan FH, Braunwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) Trial. Circulation 1987; 75:817-829
16. Ritchie JL, Davis KB, Williams DL, et al. Global and regional left ventricular function and tomographic radionuclide perfusion: the Western Washington intracoronary streptokinase in myocardial infarction trial. Circulation 1984; 70:867-875
17. Meinertz T, Kasper W, Schumacher M, et al. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988; 62:347-351
18. Pedretti R, Laporta A, Etro MD, et al. Influence of thrombolysis on signal-averaged electrocardiogram and late arrhythmic events after acute myocardial infarction. Am J Cardiol 1992; 69:866-872
19. Vatterott PJ, Hammill SC, Bailey KR, et al. Late potentials on signal-averaged electrocardiograms and patency of the infarct-related artery in survivors of acute myocardial infarction. J Am Coll Cardiol 1991; 17:330-337
20. Zimmermann M, Adamec R, Ciaroni S. Reduction in the frequency of ventricular late potentials after acute myocardial infarction by early thrombolytic therapy. Am J Cardiol 1991; 67:697-703
21. Gang ES, Lew AS, Hong M, et al. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 1989; 321:712-716
22. Bourke JP, Young AA, Richards DAB, et al. Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution. J Am Coll Cardiol 1990; 16:1703-1710
23. Sager PT, Perlmutter RA, Rosenfeld LE, et al. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 1988; 12:19-24
24. Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. Am J Cardiol 1989;64:155-160
25. Huikuri HV, Koistinen MJ, Airaksinen KEJ, et al. Significance of perfusion of the infarct related coronary artery for susceptibility to ventricular tachyarrhythmias in patients with previous myocardial infarction. Heart 1996; 75:17-22
26. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary bypass surgery: survival of patients with a low ejection fraction. N Engl J Med 1985; 312:1665-1671
27. Wiesfeld ACP, Crijns HJGM, Hillege HL, et al. The clinical significance of coronary anatomy in post-infarct patients with late sustained ventricular tachycardia or ventricular fibrillation. Eur Heart J 1995; 16:818-824
28. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implantable cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337:1569-1575
29. Bigger JT, Whang W, Rottman JN, et al. Mechanisms of death in the CABG Patch Trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999; 99:1416-1421
30. Bigger JT, Rottman JN, Whang W, et al. The CABG Patch Trial Investigators: CABG surgery unlinked the arrhythmic substrate from arrhythmic outcomes in the CABG trial. Circulation 1999; 100(suppl):I-366-I-367
31. Pratt CM, Greenway PS, Schoenfeld MH, et al. Exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996; 93:519-524